Level Bio AB (publ)'s latest marketcap:
As of 08/31/2026, Level Bio AB (publ)'s market capitalization has reached $1.91 M. According to our data, Level Bio AB (publ) is the 49057th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 1.91 M |
| Revenue (ttm) | 3.59 M |
| Net Income (ttm) | 496,219.1 |
| Shares Out | 68.4 M |
| EPS (ttm) | 0 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 10/23/2026 |
Level Bio AB (publ)'s yearly market capitalization.
| Date | Market Cap(kr) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 08/31/2026 | kr18.33 M | $1.91 M | -15.33% | 49057 |
| 12/30/2025 | kr20.52 M | $2.17 M | 8.7% | 42696 |
| 12/30/2024 | kr18.88 M | $1.7 M | -27.02% | 43574 |
| 12/29/2023 | kr25.87 M | $2.55 M | -45.31% | 41299 |
| 12/30/2022 | kr47.3 M | $4.51 M | -70.97% | 38570 |
| 12/30/2021 | kr162.94 M | $17.92 M | 142.83% | 33223 |
| 12/30/2020 | kr67.1 M | $0 | 284.85% | 32741 |
| 12/30/2019 | kr17.43 M | $1.85 M | -64.89% | 32529 |
| 12/28/2018 | kr49.66 M | $5.58 M | -21.01% | 29461 |
| 12/29/2017 | kr62.87 M | $7.65 M | 19% | 28267 |
Company Profile
About Level Bio AB (publ)
Level Bio AB (publ) is a diagnostics company specializing in the design, development, and distribution of innovative diagnostic products across the Nordic region and internationally.
Core Business Activities
- Distribution: Supplies equipment, consumables, and reagents for molecular biology, research, and diagnostics in Sweden and the Nordics.
- Product Development: Focuses on genetic fetal diagnostics, as well as miscarriage and infertility diagnostics.
- Specialized Solutions: Engages in developing products for congenital heart defects.
Key Product Portfolio
- Rob: An automated 96/384 qPCR setup for precision diagnostics.
- BugScreener: A system designed to screen for methicillin-resistant Staphylococcus aureus (MRSA).
- aAmp: A thermal cycler leveraging SuperConvection technology for highly accurate PCR assays.
Company Background
Originally founded in 1998 as AlphaHelix Molecular Diagnostics AB (publ), the company rebranded to Level Bio AB (publ) in May 2024. Headquartered in Stockholm, Sweden, it continues to drive advancements in diagnostic solutions.
Frequently Asked Questions
-
What is Level Bio AB (publ)'s (NGM-LEVBIO) current market cap?As of 08/31/2026, Level Bio AB (publ) (including the parent company, if applicable) has an estimated market capitalization of $1.91 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Level Bio AB (publ) (NGM-LEVBIO) rank globally by market cap?Level Bio AB (publ) global market capitalization ranking is approximately 49057 as of 08/31/2026. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.